CRL · Charles River Laboratories International, Inc.

This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 3, 2025.

This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 4, 2026.

This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026.

This transaction was executed in multiple trades at prices ranging from $261.00 to $261.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

This transaction was executed in multiple trades at prices ranging from $264.91 to $265.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

This transaction was executed in multiple trades at prices ranging from $263.39 to $264.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

This transaction was executed in multiple trades at prices ranging from $262.26 to $262.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

This transaction was executed in multiple trades at prices ranging from $259.97 to $260.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

This transaction was executed in multiple trades at prices ranging from $258.77 to $259.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

This sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 4, 2026.

This sale occurred pursuant to a Rule 10b5-1 Trading Plan that was adopted by the reporting person on March 6, 2026.

Reflects the exempt transfer pursuant to Rule 16a-13 of 153,361 shares held by the reporting person to a revocable trust controlled by the reporting person.

Reflects the exempt transfer pursuant to Rule 16a-13 of 20,000 shares held by the reporting person to a revocable trust controlled by the reporting person.

Reflects the exempt transfer pursuant to Rule 16a-13 of 1,529 shares held by the reporting person to a revocable trust controlled by the reporting person.

Reflects the exempt transfer pursuant to Rule 16a-13 of 20,000 shares held by the reporting person to a revocable trust controlled by the reporting person.

Reflects the exempt transfer pursuant to Rule 16a-13 of 10,000 shares held by the reporting person's spouse to a revocable trust controlled by the reporting person's spouse.

Reflects the exempt transfer pursuant to Rule 16a-13 of 1,529 shares held by the reporting person to a revocable trust controlled by the reporting person.

Reflects the exempt transfer pursuant to Rule 16a-13 of 3,386 shares held by the reporting person to a revocable trust controlled by the reporting person.

Reflects the exempt transfer pursuant to Rule 16a-13 of 3,386 shares held by the reporting person to a revocable trust controlled by the reporting person.

Reflects the exempt transfer pursuant to Rule 16a-13 of 153,361 shares held by the reporting person to a revocable trust controlled by the reporting person.

Reflects the exempt transfer pursuant to Rule 16a-13 of 10,000 shares held by the reporting person's spouse to a revocable trust controlled by the reporting person's spouse.

The grant was made in lieu of director service fees for the term commencing May 5, 2026. The restricted stock units vest upon the earlier of 6/2/2027, or the business day prior to the Company's next annual meeting of shareholders.